Acino International AG

Acino International AG

Acino International AG

Overview
Date Founded

1962

Headquarters

Dornacherstrasse 114,Aesch, Basel-Landschaft (Basle Country) 4147

Type of Company

Private

Employees (Worldwide)

788

Industries

Pharmaceuticals

Company Description

Acino International AG develops and manufactures pharmaceuticals in novel drug delivery form. It provides drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. It also offers abelcet, bactiflox, clopacin, dolonica, hydronica, neurorubine, olfen and spasfon. The company was founded in 1836 and is headquartered in Zurich, Switzerland.

Contact Data
Trying to get in touch with decision makers at Acino International AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Chief Legal & Compliance Officer

Chief Human Resources Officer

Chief Human Resources Officer

Head of Global Medical & Regulatory Affairs

Head of Corporate Communications

Head-Corporate Business Development

Vice Chairman

Paths to Acino International AG
Potential Connections via
Relationship Science
You
Acino International AG
Recent Transactions
Details Hidden

Pharma Strategy Partners GmbH, Acino Pharma AG purchase Takeda Pharmaceuticals Co. Ltd. /Primary Care Portfolio Bus from Takeda Pharmaceutical Co., Ltd.

Details Hidden

Pharma Strategy Partners GmbH, Acino Pharma AG purchase Litha Healthcare Group Ltd. from Endo International Plc

Details Hidden

Acino International AG, Avista Capital Partners, Pharma Strategy Partners GmbH, Nordic Capital Ltd. purchase Takeda Pharma AS from Takeda Pharmaceutical Co., Ltd.

Transaction Advisors
Accountant

Advised onAcino International AG purchases CIMEX Pharma AG

Legal Advisor

Advised onAvista Capital Partners, Pharma Strategy Partners GmbH, Nordic Capital Ltd., Nordic Capital (extinct) purchase Acino International AG

Legal Advisor

Advised onPharma Strategy Partners GmbH, Acino Pharma AG purchase Litha Healthcare Group Ltd. from Endo International Plc

Legal Advisor

Advised onAvista Capital Partners, Pharma Strategy Partners GmbH, Nordic Capital Ltd., Nordic Capital (extinct) purchase Acino International AG

Associate

Advised onAvista Capital Partners, Pharma Strategy Partners GmbH, Nordic Capital Ltd., Nordic Capital (extinct) purchase Acino International AG

Consultant

Advised onAvista Capital Partners, Pharma Strategy Partners GmbH, Nordic Capital Ltd., Nordic Capital (extinct) purchase Acino International AG

Clients

Saudi Chemical Co. engages in the manufacture and sale of explosives and related products for civil and military uses.It operates through the following segments: Explosives, Medicines and Detergents, and Production of Ammonium Nitrate. Its products include electronic detonators, blasting agents, initiation systems, seismic explosives, and accessories.The company was founded on March 25, 1972 and is headquartered in Riyadh, Saudi Arabia.

Investments
Details Hidden

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Details Hidden

Genedata AG transforms data into intelligence with a portfolio of advanced software solutions. Its products include biologics, screener, expressionist, profiler, analyst, phylosospher, selector, imagence and bioprocess. The firm offers data analysis, information technology, training, software, development and hosting services to pharmaceutical, agrochemical, Industrial biotechnology companies and non-profit research organizations. The company was founded by Othmar Pfannes in 1997 and is headquartered in Basel, Switzerland.

Details Hidden

Anadys Pharmaceuticals, a biopharmaceutical company, develops medicines for the treatment of hepatitis C.

Investors
Details Hidden

Nordic Capital is a hands-on, long-term manager which aims to create value primarily in middle-market companies based in the Nordic region by creating new industrial combinations, pursuing strategic repositioning or exploring internationalization opportunities. The firm supports the internationalization process of their investee companies, often pursuing follow-up investments outside of the Nordic countries.Nordic Capital partners with investee company management, acting as a catalyst to enhance long-term profit. The firm draws on the expertise and contacts of their network of industrial advisers when analyzing strategic opportunities and nominating board members to their investee companies, setting mutual goals such as strategic add-on acquisitions, aggressive organic growth or establishing an international sales organization with company management.

Details Hidden

Constitution Capital Partners (CCP) makes co-investments in North American small to mid-cap companies. They generally seek to invest alongside premier buyout funds in these transactions. They expect that their co-investment funds will be diversified across managers, sectors and vintage years. For these investments, CCP tends to invest in the following sectors: consumer discretionary, industrial and healthcare.

Details Hidden

Avista invests in middle market healthcare companies located in the US. The firm target companies in sectors such as pharmaceuticals, medical devices, outsourced pharmaceutical services, distribution, and consumer-driven healthcare. They provides financing for leveraged buyouts, build-ups, structured investments and growth capital requirements with an investment size ranging from USD50 to USD300 million per transaction. They consider both controlling and minority investments.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Acino International AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Acino International AG's profile does not indicate a business or promotional relationship of any kind between RelSci and Acino International AG.